Dr. Sunil Dhawan MD
Clinical Assistant Professor of Dermatology, LELAND STANFORD JUNIOR UNIVERSITY
Member of the Healthcare Council
Council Member Biography
Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, onychomycosis, actinic keratosis, lasers, fillers, cosmetic dermatology, and managed care. Dr. Dhawan runs the clinical trial division in his group practice- The Center for Dermatology, Cosmetic and Laser Surgery, Inc, where he has performed over 60 trials for all the major pharmaceutical companies. He has consulted for companies such as Allergan, Obagi, Connetics, Galderma, Astellas, Medicis, Amgen, and Stiefel. Dr. Dhawan is on the governing board of the local physician run IPA, as well as the utilization committee of the largest IPA in the Silicon Valley. He has also been President of a local physician's organization and has served on several boards. (This is me - Update Profile)
Employment History
- 1992 - Unspecified
- Clinical Assistant Professor of Dermatology, LELAND STANFORD JUNIOR UNIVERSITY
- 1990 - Unspecified
- Dermatologist, East Bay Dermatology Medical Group Inc
GLG NewsSM Analyses by Sunil Dhawan
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Obagi Medical Products recent Q1 2011 results have some important implications
May 7, 2011
Obagi Medical Products Reports First Quarter 2011 Results | finance.yahoo.com
The recent first quarter call from Obagi Medical Products indicates that the legal battles with the founder appear to be over. Also a ban on hydroquinone products in Texas may have a temporary minor effect on the company, but can and should be resolved in a favorable manner.
-
Leo pharma's phase 3 actinic keratosis trial shows promise
December 25, 2009
Positive results for LEO Pharma’s phase III actinic (solar) keratosis trials on the face and scalp | www.pipelinereview.com
This trial of Leo pharma's new Ak topical shows great promise. The results were positive, and further trials on non facial areas are ongoing. The advantage of this product is that treatment only requires 3 days, though the product can be irritating. Other products for actinic keratosis can also irritate. This will be the second product from Leo, to be released in 2012,as they will be marketing Taclonex as well, as of 2010. This is the beginning of a strong dermatology company in the US.
-
November 19, 2009
Leo Pharma completes merger pact with Peplin | www.pharmabiz.com
The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.
-
Presta Trial shows good results for Enbrel
October 14, 2009
New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com
This trial showed predicatably good results for Enbrel in patients with psoriasis and psoriatic arthritis. This included improvement in signs and symptoms and quality of life. This will increase sales of Enbrel in the short term. However the two newer agents, Humira and Stelara have better efficacy, and more convenient dosing regimens. Both will be doing similar studies.
-
Will the withdrawl of Efalizumab effect the biologic market?
April 15, 2009
Efalizumab withdrawn from US Market | www.medscape.com
This article is important in that the withdrawal of efalizumab by Genentech was appropriate in view of its serious side effect of progressive multifocal leukoencephalopathy (PML). This biologic agent was already declining in usage because of its other side effects, and the presence of other strong competitors with equal or higher efficacy and less side effects. This was to be compounded by the impending release of ustekinumab
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.